HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

Effects of HMG CoA reductase inhibitor on cholesterol absorption in obesity: Implications for the regulation of very-low-density lipoprotein B-100 metabolism

Atherosclerosis Supplements ◽

10.1016/s1567-5688(02)80779-6 ◽

2002 ◽

Vol 3 (2) ◽

pp. 235

Keyword(s):

Reductase Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Cholesterol Absorption ◽

Very Low Density Lipoprotein ◽

Low Density ◽

Hmg Coa Reductase ◽

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

Atherosclerosis ◽

10.1016/0021-9150(91)90017-w ◽

1991 ◽

Vol 87 (2-3) ◽

pp. 147-157 ◽

Cited By ~ 40

Author(s):

Jiana Yuan ◽

Michael Y. Tsai ◽

Janet Hegland ◽

Donald B. Hunninghake

Keyword(s):

Reductase Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Low Density ◽

Hmg Coa Reductase ◽

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

Atherosclerosis ◽

10.1016/0021-9150(94)05439-p ◽

1995 ◽

Vol 113 (2) ◽

pp. 157-166 ◽

Cited By ~ 125

Author(s):

Jose M. Ordovas ◽

Jose Lopez-Miranda ◽

Francisco Perez-Jimenez ◽

Carmen Rodriguez ◽

Jong-Soon Park ◽

...

Keyword(s):

Apolipoprotein E ◽

Reductase Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Inhibitor Therapy ◽

Low Density ◽

Hmg Coa Reductase ◽

Lipoprotein Response ◽

The HMG-CoA Reductase Inhibitor Cerivastatin Lowers Advanced Glycation End Products in Patients with Type 2 Diabetes

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-2007-973830 ◽

2007 ◽

Vol 115 (06) ◽

pp. 372-375 ◽

Cited By ~ 9

Author(s):

H. Scharnagl ◽

T. Stojakovic ◽

K. Winkler ◽

S. Rosinger ◽

W. März ◽

...

Keyword(s):

Type 2 Diabetes ◽

Advanced Glycation End Products ◽

Reductase Inhibitor ◽

Advanced Glycation ◽

Hmg Coa Reductase ◽

Glycation End Products ◽

End Products ◽

Systemic administration of HMG-CoA reductase inhibitor protects the blood–retinal barrier and ameliorates retinal inflammation in type 2 diabetes

Experimental Eye Research ◽

10.1016/j.exer.2009.02.013 ◽

2009 ◽

Vol 89 (1) ◽

pp. 71-78 ◽

Cited By ~ 42

Author(s):

Jingming Li ◽

Joshua J. Wang ◽

Danyang Chen ◽

Robert Mott ◽

Qiang Yu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Reductase Inhibitor ◽

Systemic Administration ◽

Blood Retinal Barrier ◽

Hmg Coa Reductase ◽

Retinal Inflammation ◽

Efficacy of Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes

Diabetes Care ◽

10.2337/diacare.28.12.2980-a ◽

2005 ◽

Vol 28 (12) ◽

pp. 2980-2981 ◽

Cited By ~ 15

Author(s):

T. Kawai ◽

M. Tokui ◽

O. Funae ◽

S. Meguro ◽

S. Yamada ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glucose Metabolism ◽

Reductase Inhibitor ◽

Hmg Coa Reductase ◽

Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro

Biochemical Pharmacology ◽

10.1016/s0006-2952(98)00341-4 ◽

1999 ◽

Vol 57 (6) ◽

pp. 697-703 ◽

Cited By ~ 53

Author(s):

Kuniharu Suzumura ◽

Mikiko Yasuhara ◽

Keiko Tanaka ◽

Toshikazu Suzuki

Keyword(s):

Protective Effect ◽

Reductase Inhibitor ◽

Coenzyme A ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Oxidative Modification ◽

Low Density ◽

The Relationship Between Apolipoprotein B-100 and Low-Density Lipoprotein Cholesterol after Treatment with an HMG CoA Reductase Inhibitor

American Journal of Clinical Pathology ◽

10.1093/ajcp/92.4.479 ◽

1989 ◽

Vol 92 (4) ◽

pp. 479-483 ◽

Cited By ~ 3

Author(s):

Stanley S. Levinson ◽

Roger D. Blevins ◽

Michael P. Smith ◽

Melvin Rubinfire ◽

James J. Maciejko

Keyword(s):

Apolipoprotein B ◽

Reductase Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Low Density Lipoprotein Cholesterol ◽

Coa Reductase ◽

The Relationship

SYNERGISTIC REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL WITH COMBINED HMG-COA REDUCTASE INHIBITOR AND AEROBIC EXERCISE THERAPY IN OBESE, HYPERCHOLESTEROLEMIC MALES

Medicine & Science in Sports & Exercise ◽

10.1097/00005768-200205001-00273 ◽

2002 ◽

Vol 34 (5) ◽

pp. S50

Author(s):

K P. Honeal ◽

I W. Waters ◽

J S. Hallam ◽

J Fullenwider ◽

C McIntosh ◽

...

Keyword(s):

Aerobic Exercise ◽

Exercise Therapy ◽

Reductase Inhibitor ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Low Density ◽

Low Density Lipoprotein Cholesterol ◽

Intense Cholesterol Lowering Therapy with a HMG-CoA Reductase Inhibitor does not Improve Nitric Oxide Dependent Endothelial Function in Type-2-Diabetes

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-2005-865642 ◽

2005 ◽

Vol 113 (06) ◽

pp. 324-330 ◽

Cited By ~ 22

Author(s):

B. Balletshofer ◽

S. Goebbel ◽

K. Rittig ◽

M. Enderle ◽

I. Schmölzer ◽

...

Keyword(s):

Nitric Oxide ◽

Type 2 Diabetes ◽

Endothelial Function ◽

Reductase Inhibitor ◽

Cholesterol Lowering ◽

Hmg Coa Reductase ◽

Lowering Therapy ◽